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Abstract
From an historical point of view, combination therapy was the basis for the care of important diseases like
infection diseases or cancer. Today the “cocktail drug” of the Highly Active Anti Retroviral Therapy (HAART) has
reduced the death for HIV infection changing the outcome of such disease. Moreover, the combination of different
strategies changed the course of transplants (both in haematology and surgical transplant). Different diseases with
high social impact including cardiovascular, metabolic (obesity, hypercholesterolaemia and diabetes) and
autoimmune diseases, have better results with combinations of different drug classes of drugs. After recent
successes in the immunotherapy field (Sepuleucel-T, ipilimumab) and the new promising small molecule therapies,
cancer should be the next challenge for combination strategies.
In order to accomplish these objectives open discussion
and cooperation among companies, academic, and other
institutions will be increasingly important. For all of
these reasons, we have created a new subsection of the
Journal of Translational Medicine.
Why should a Subsection of the Journal of Translational
Medicine be dedicated to combination strategies? Because
we want to stimulate discussion over this hot topic. In
recent years, several compounds have been developed to
treat a broad number of diseases targeting a specific
mechanism. However, vast majority of common diseases
are multi-factorial and cannot realistically be controlled by
targeting a single or few pathways.
Tuberculosis treatment is a classic example of combina-
tion therapy [1]. After the discovery of Streptomycin in
1944, improvement in the effectiveness of therapy was
observed with the addition of Isoniazid, the first oral myco-
bactericidal drug in 1952 and Rifamycins in 1957. The
introduction of Rifampicin in 1970 further improved the
effectiveness of the treatment of tuberculosis. As for this
example, the main reason for the improved effectiveness of
combination therapy is prevention of the emergence of
resistance to individual drugs. Moreover, different drugs
displaying different pharmacodynamics and/or pharmaco-
kinetics could target subpopulations of mycobacteria
independently on metabolic stage or location within the
organism.
With the advent of novel immunosuppressive agents
allograft rejection is prevented in an increasingly more
effective manner with reduced toxicity [2]. Drugs like
Cyclosporin A, Tacrolimus (FK506), Voclosporin (ISA247),
Sotrastaurin (AEB071), Sirolimus, Everolimus, Mycopheno-
lic acid, Azathioprine, CP-690550, Belatacept (LEA29Y),
Alefacept Humanized LFA3-Ig, Basiliximab, Alemtuzumab,
Muromonab-CD3, Rituximab, Bortezomib Tripeptide,
Eculizumab incrementally reduced the risk of transplant
rejection when used in combination. Other important
examples of effective combinatorial approaches are repre-
sented by Human Immunodeficiency Virus (HIV) and
Hepatitis C Virus (HCV) infections. The discovery of sev-
eral classes of drugs that exert different anti-viral mechan-
isms dramatically changed the prognosis in these patients.
T h eH i g h l yA c t i v eA n t iR e t r o v i r a lT h e r a p y( H A A R T )
changed HIV infection from an incurable disease to a
chronic illness. According to Julio Montaner, director of
the British Columbia Centre for Excellence in HIV/AIDS,
“results show a strong and significant association between
increased HAART coverage, reduced community viral
load, and decreased number of new HIV diagnoses per
year in the population of a Canadian province” [3]. “While
waiting for an effective vaccine, experiences such as those
reported today should be strongly considered by clinicians,
national and international agencies, policy makers, and all
parties involved in the development of treatment
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HAART might play an important part in the future control
of the HIV epidemic” wrote Franco Maggiolo and Sebas-
tiano Leone [4].
Combination therapy with several drugs is the approach
used in several cardiovascular diseases. Acute Coronary
Syndrome [5] and Pulmonary Arterial Hypertension [6]
are classical examples. Moreover, an abundance of studies
demonstrate additive antihypertensive benefit by combin-
ing 2 agents of different classes in Essential Hypertension.
The extra blood pressure reduction from combining drugs
from 2 different classes is approximately 5 times greater
than doubling the dose of 1 drug [7]. This is particularly
true for thiazide diuretics, which significantly improve
blood pressure control when used in combination with
most if not all other classes of agents [8]. Often Cardiac
Disease are associated with other metabolic diseases like
hypercholesterolaemia and diabetes; each of them is
further and effectively treated with the association of
different compounds [9,10].
Even autoimmune diseases can benefit from combina-
tion therapy. Crohn’s disease [11] and rheumatoid arthri-
tis (RA) are good examples of such an approach. In fact,
recently antitumour necrosis factor (anti-TNF) therapies
are now routinely used in the management of rheuma-
toid arthritis in patients for whom traditional disease-
modifying antirheumatic drugs (DMARDs) have failed. A
better response has been demonstrated with any of three
anti-TNF therapies [etanercept (ETN), infliximab (INF)
and adalimumab (ADA)] when used in combination with
methotrexate (MTX) than when used as monotherapies
(Nixon). Moreover, combining anti-TNF with MTX in
combination with one or more other DMARDs [sulfasa-
lazine (SSZ), hydroxychloroquine (HCQ) or both]
resulted in better long-term treatment persistence [12].
But this is only the beginning! Treatment of cancer may
indeed represent the field where combination strategies
surely play a crucial role. In fact, a combination of surgery,
radiotherapy, and chemotherapy has been the standard
care for the treatment of breast, ovarian, and head and
neck cancer. However, in the last decade, the approaches
to cancer therapy have changed. In 1998, the approval of
trastuzumab for the treatment of breast cancer was a mile-
stone which established a new class of cancer treatment
that utilizes immune based mechanisms rather than cyto-
toxic drugs. In 2001, imatinib was approved for the treat-
ment of chronic myeloid leukemia and its utilization had a
dramatic impact on long term survival. Since then,
new drugs targeting specific mechanisms have been
employed for the treatment of several types of cancer. In
some cases promising results had an impact on subse-
quent approaches (bevacizumab, cetuximab, sorafenib,
sutent) whereas other drugs failed to reach the expected
results (gefitinib, CpG). Ipilimumab, a further example: a
target agent that, through an indirect action on the
immune system, induces anti-neoplastic activity against
cancers such as melanoma, prostate cancer and NSCLC,
has recently obtained Food and Drug Administration
(FDA) approval for advanced melanoma treatment [13].
Together with other recent successes in immunotherapy,
2010 became a milestone year for the biological therapy of
cancer. In 2010, the first anti-cancer vaccine received FDA
approval (Sepuleucel-T for the treatment of prostate can-
cer) [14] as well as Vemurafinib (PLX4032) or the specific
inhibitor of mutated BRAF (V600E) has demonstrated dra-
matic effectiveness in melanoma patients [15]. Neverthe-
less, we have new interesting targeted agents (ALK
inhibitor, MEK, PI3K and AKT inhibitors, anti-PD1,
demethylating agents, oncolytic viral vaccine, etc.) that are
ready to be used in clinical trial. Thus, we have been treat-
ing cancer attacking one pathways/mechanism at a time
disregarding the complexity, redundancy, and compensa-
tory mechanisms typical of this rapidly evolving disease.
Thus far, not many examples of combinatorial approaches
have been tested; it would be highly desirable to follow the
successful example of the treatment of HIV with HAART.
A multi-target therapy could combine novel agents with
standard chemotherapy or novel agents with different
mechanisms or action. Sequential administration of differ-
ent agents may inhibit cancer cell growth at different
check points, while other agents may inhibit neo-angio-
genesis, survival of malignant cells or metastases, poten-
tially converting cancer into a chronic disease [16].
Toxicity will surely represent one limitation In fact, if
we look at HAART, toxicity from the combination of
several drugs should not be overlooked [17]. On the
other hand, it is known that the combination of differ-
ent strategies may amplify the various side effects of
e v e r ys i n g l ed r u g s .H o w e v e r ,w em u s tb er e a d yt of a c e
such issues if the goal is to turn an incurable lethal dis-
ease into a manageable disease.
The challenge will be to test novel combinations particu-
larly for drugs that have not been as yet licensed. Clinical
trials are often influenced by the financial pressure aimed
at demonstrating product effectiveness for licensing rather
than systematically designing trials to evaluate the
mechanisms of action of the therapy as well as whether
biological end-point are achieved or why treatment might
have failed. Such information could provide clues for the
design of more sophisticated follow up studies using novel
agents. Thus, several drugs tested as single agents risk
being withdrawn and becoming unavailable for continue
research by early negative clinical results from studies that
had not been planned carefully to understand the potential
activity of the drug when administered to human beings. It
may be important to rescue drugs that “failed” when used
as single agents to study their effectiveness in combination
with others that have different but potentially synergistic
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good example is the association of the combination
between pegylated interferon-alpha and Ribavarin, two
drugs that alone demonstrated very minimal benefit, for
the treatment of chronic HCV [18].
Testing drugs in combination may be hampered not
only by scientific or regulatory hurdles, but also by the
difficulty of obtaining the interest and participatin of
individual companies. Segregation of products according
to market niches and proprietary arguments is limiting
the utilization of promising products in combination
and their potential application to broad patient popula-
tions as licensable combination therapy.
For all the above reasons, we are creating a subsection of
the Journal of Translational Medicine dedicated to combi-
nation strategies as a forum to stimulate discussion
between academia, industry and other institutions in order
to emphasis the identification of clinical trial strategies uti-
lizing combinations of treatment. Although cancer and
infectious diseases have been recently in the front line of
the interest for combinatorial approaches, we recognize
that other disciplines such as cardiovascular, autoimmune,
metabolic and other chronic disorders characterized by
complex biology will benefit of drug combination
approaches in next future. Therefore, this subsection is
now open to submissions relevant to this topic, indepen-
dently on the target disease.
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